Gilead Sciences (GILD) : Pictet North America Advisors Sa reduced its stake in Gilead Sciences by 17.88% during the most recent quarter end. The investment management company now holds a total of 145,644 shares of Gilead Sciences which is valued at $11,602,001 after selling 31,704 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Gilead Sciences makes up approximately 2.57% of Pictet North America Advisors Sa’s portfolio.
Other Hedge Funds, Including , Koshinski Asset Management boosted its stake in GILD in the latest quarter, The investment management firm added 1,462 additional shares and now holds a total of 8,630 shares of Gilead Sciences which is valued at $687,466. Gilead Sciences makes up approx 0.35% of Koshinski Asset Management’s portfolio.Tokio Marine Asset Management Co Ltd reduced its stake in GILD by selling 3,576 shares or 8.19% in the most recent quarter. The Hedge Fund company now holds 40,096 shares of GILD which is valued at $3,279,452. Gilead Sciences makes up approx 0.33% of Tokio Marine Asset Management Co Ltd’s portfolio.Burt Wealth Advisors reduced its stake in GILD by selling 27 shares or 1.28% in the most recent quarter. The Hedge Fund company now holds 2,090 shares of GILD which is valued at $180,890. Gilead Sciences makes up approx 0.16% of Burt Wealth Advisors’s portfolio.First Western Capital Management Co reduced its stake in GILD by selling 25,234 shares or 38.99% in the most recent quarter. The Hedge Fund company now holds 39,481 shares of GILD which is valued at $3,385,496. Gilead Sciences makes up approx 1.21% of First Western Capital Management Co’s portfolio.
Gilead Sciences opened for trading at $80.56 and hit $81.1757 on the upside on Friday, eventually ending the session at $81, with a gain of 0.51% or 0.41 points. The heightened volatility saw the trading volume jump to 82,27,939 shares. Company has a market cap of $106,892 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.